Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

Gilead And Tentarix Enter Three Collaboration Agreements Worth US$66M To Develop Cancer And Inflammation Biologics

Aug 15, 2023

Gilead and Tentarix Biotherapeutics announced have entered three multi-year agreements to leverage Tentarix’s Tentacles® platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases.  Gilead said that the collaboration may provide access to next-generation, multi-specific biologics.  Tentarix will receive $66M in upfront payments and an equity investment from Gilead, whilst Gilead can acquire up to three select Tentarix subsidiaries containing the programs developed under the collaborations for $80M each.

On 7 August 2023 Gingko Bioworks and Merck announced a US$490M collaboration to improve biologic manufacturing.